Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomepromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.82 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.46 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.82 |
| ▸ | HTR1A | P08908 | 4/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.82 |
| ▸ | DRD1 | P21728 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.82 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomepromazine SCHEMBL29727144 | 1.00 | LMNA (0.82) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29697036 | 1.00 | LMNA (0.82) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL27701483 | 0.93 | LMNA (0.88) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29508092 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL8762418 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL23859840 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL6944555 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29425180 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL25462 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29384983 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 469 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220050117-A1 | GLX-DERIVED MOLECULE DETECTION | GLX ANALYTIX APS (DK) | 2022-02-17 | — | — | US | claimed |
| EP-2743263-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOMEPROMAZINE MALEATE | ZCL CHEMICALS LTD (IN) | 2018-01-03 | — | — | EP | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| EP-2743263-A1 | An improved process for the preparation of levomepromazine maleate | ZCL Chemicals Ltd. (IN) | 2014-06-18 | — | — | EP | claimed |
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| EP-0251904-B1 | PROCESS FOR THE PREPARATION OF ACIDIC LEVOMEPROMAZINE MALEATE | RHONE-POULENC SANTE (FR) | 1990-01-10 | — | — | EP | claimed |
| US-4798895-A | Process for preparing levomepromazine hydrogen maleate | RHONE-POULENC SANTE (FR) | 1989-01-17 | — | — | US | claimed |
| US-20250288541-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2025-09-18 | — | — | US | disclosed |
| US-12384770-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-12 | — | — | US | disclosed |
| US-12357590-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-12350242-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2025-07-08 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250052770-A1 | GLX-DERIVED MOLECULE DETECTION | GLX ANALYTIX APS (DK) | 2025-02-13 | — | — | US | disclosed |
| US-20250042870-A1 | DP ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-02-06 | — | — | US | disclosed |
| US-12202829-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240343721-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-17 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-12084436-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-10 | — | — | US | disclosed |
| US-12064402-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2024-08-20 | — | — | US | disclosed |
| EP-3854781-B1 | DP ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-11958845-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-112500301-B | Regulator for longitudinal behavior | 以西结·戈兰 | 2024-02-13 | — | — | CN | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| EP-3494229-B1 | HIGH THROUGHPUT CELL-BASED SCREENING FOR APTAMERS | MEIRAGTX UK II LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230183227-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-15 | — | — | US | disclosed |
| EP-3018123-B1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-10 | — | — | EP | disclosed |
| US-11639354-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2023-05-02 | — | — | US | disclosed |
| WO-2023037254-A1 | METHODS AND COMPOUNDS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS | DIDENKO KIRILL (MX) | 2023-03-16 | — | — | WO | disclosed |
| US-20230065720-A1 | High Throughput Cell-Based Screening for Aptamers | MeiraGTx Gene Regulation Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| US-11453661-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-27 | — | — | US | disclosed |
| EP-4034536-A1 | 2-ISOINDOL-1,3,4-OXADIAZOLE DERIVATIVES USEFUL AS HDAC6 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-114846012-A | 2-isoindole-1, 3, 4-oxadiazole derivatives useful as HDAC6 inhibitors | 武田药品工业株式会社 | 2022-08-02 | — | — | CN | disclosed |
| US-20220204468-A1 | DP ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-11371077-B2 | High throughput cell-based screening for aptamers | MEIRAGTX UK II LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| WO-2022124243-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | 東和薬品株式会社 | 2022-06-16 | — | — | WO | disclosed |
| US-11319296-B2 | DP antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20220098180-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-31 | — | — | US | disclosed |
| US-20220050117-A1 | GLX-DERIVED MOLECULE DETECTION | GLX ANALYTIX APS (DK) | 2022-02-17 | — | — | US | disclosed |
| US-20220033371-A1 | DP ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| EP-3919055-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-20210330609-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2021-10-28 | — | — | US | disclosed |
| US-20210330607-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2021-10-28 | — | — | US | disclosed |
| US-20210330608-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2021-10-28 | — | — | US | disclosed |
| EP-3181616-B1 | CELLULOSE MICROPOWDER | ASAHI CHEMICAL IND (JP) | 2021-09-15 | — | — | EP | disclosed |
| US-20210277030-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| US-11077072-B2 | Binge behavior regulators | Clearmind Medicine Inc. | 2021-08-03 | — | — | US | disclosed |
| EP-3854781-A1 | DP ANTAGONIST | ONO Pharmaceutical Co., Ltd. (JP) | 2021-07-28 | — | — | EP | disclosed |
| US-11053262-B2 | Heterocyclic amide compounds having RORyT inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-06 | — | — | US | disclosed |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2021-06-17 | — | — | US | disclosed |
| EP-3831811-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2021-06-09 | — | — | EP | disclosed |
| CN-112739680-A | DP antagonists | 小野药品工业株式会社 | 2021-04-30 | — | — | CN | disclosed |
| US-10987365-B2 | Compositions and methods for the treatment of pain | GM PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2021060567-A1 | 2-ISOINDOL-1,3,4-OXADIAZOLE DERIVATIVES USEFUL AS HDAC6 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | WO | disclosed |
| US-20210094944-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| CN-109923101-B | Cyclic compound | 武田药品工业株式会社 | 2021-03-09 | — | — | CN | disclosed |
| US-20210046044-A1 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | MCKINNEY ANTHONY ALEXANDER (US) | 2021-02-18 | — | — | US | disclosed |
| CN-108026088-B | Oxadiazole derivatives as HDAC inhibitors | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| EP-2486917-B1 | COATING FILM, AND GRANULES AND TABLETS EACH UTILIZING SAME | ASAHI CHEMICAL IND (JP) | 2020-11-25 | — | — | EP | disclosed |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-29 | — | — | US | disclosed |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3705469-A1 | BINGE BEHAVIOR REGULATORS | GOLAN, Ezekiel (CA) | 2020-09-09 | — | — | EP | disclosed |
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-18 | — | — | US | disclosed |
| US-10738004-B2 | Cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-11 | — | — | US | disclosed |
| WO-2020158762-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-08-06 | — | — | WO | disclosed |
| US-20200239940-A1 | High Throughput Cell-Based Screening For Aptamers | MEIRAGTX UK II LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| EP-3661931-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| WO-2020059790-A1 | DP ANTAGONIST | 小野薬品工業株式会社 | 2020-03-26 | — | — | WO | disclosed |
| EP-3325475-B1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-18 | — | — | EP | disclosed |
| EP-3230255-B1 | BINGE BEHAVIOR REGULATORS | GOLAN EZEKIEL (CA) | 2020-03-18 | — | — | EP | disclosed |
| WO-2020027225-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2020-02-06 | — | — | WO | disclosed |
| EP-3066094-B1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-08 | — | — | EP | disclosed |
| EP-3325490-B1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2019-12-18 | — | — | EP | disclosed |
| US-10472376-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-12 | — | — | US | disclosed |
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| CN-106795118-B | Heterocyclic compound and their purposes as relevant orphan receptor (ROR) the GAMMA-T inhibitor of retinoids | 武田药品工业株式会社 | 2019-10-08 | — | — | CN | disclosed |
| US-10406123-B2 | Binge behavior regulators | CLEARMIND LABS CORP. (CA) | 2019-09-10 | — | — | US | disclosed |
| US-10406146-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190233370-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-01 | — | — | US | disclosed |
| US-10357484-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-23 | — | — | US | disclosed |
| EP-3511320-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-17 | — | — | EP | disclosed |
| CN-109923101-A | Cyclic compound | 武田药品工业株式会社 | 2019-06-21 | — | — | CN | disclosed |
| EP-3494229-A2 | HIGH THROUGHPUT CELL-BASED SCREENING FOR APTAMERS | Meiragtx UK II Limited (GB) | 2019-06-12 | — | — | EP | disclosed |
| US-10308643-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| EP-2184056-B1 | PROCESS FOR PRODUCTION OF TABLETS CONTAINING BOTH CRYSTALLINE CELLULOSE AND GRANULES | ASAHI CHEMICAL IND (JP) | 2019-04-24 | — | — | EP | disclosed |
| US-20190054042-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2019-02-21 | — | — | US | disclosed |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| WO-2019027054-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | WO | disclosed |
| US-20190008836-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-10 | — | — | US | disclosed |
| US-10137096-B2 | Binge behavior regulators | CLEARMIND LABS CORP. (CA) | 2018-11-27 | — | — | US | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| US-20180296527-A1 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | ETHISMOS RESEARCH, INC. | 2018-10-18 | — | — | US | disclosed |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-09 | — | — | US | disclosed |
| US-10081624-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-09-25 | — | — | US | disclosed |
| US-20180263967-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-09-20 | — | — | US | disclosed |
| CN-105899505-B | Pyrazoles for the treatment of autoimmune disorders | 武田药品工业株式会社 | 2018-08-28 | — | — | CN | disclosed |
| US-10053468-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20180222896-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-09 | — | — | US | disclosed |
| CN-108368127-A | 1,2,3,4- tetrahydrochysene -1,7- naphthyridines -8- the amine derivatives of 1- substitutions and its purposes as EP4 receptor antagonists | 武田药品工业株式会社 | 2018-08-03 | — | — | CN | disclosed |
| US-20180215754-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-02 | — | — | US | disclosed |
| US-10016367-B2 | Cellulose micropowder | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-3342772-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-10000488-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-3325475-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3327019-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325490-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| CN-108026088-A | Oxadiazole derivatives as HDAC inhibitors | 武田药品工业株式会社 | 2018-05-11 | — | — | CN | disclosed |
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| WO-2018070874-A1 | MEANS AND METHODS FOR REDUCING OR AVOIDING ANTIBIOTIC RESISTANCE AND SPREAD OF VIRULENCE IN HUMAN PATHOGENS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2018-04-19 | — | — | WO | disclosed |
| US-20180099000-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | MILLENNIUM PHARM INC (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180085326-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2018-03-29 | — | — | US | disclosed |
| CN-107835800-A | cyclic compound | 武田药品工业株式会社 | 2018-03-23 | — | — | CN | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| EP-3294706-A1 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| WO-2018030550-A1 | HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | WO | disclosed |
| US-9890145-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| WO-2018025085-A2 | HIGH THROUGHPUT CELL-BASED SCREENING FOR APTAMERS | MEIRAGTX UK II LIMITED (GB) | 2018-02-08 | — | — | WO | disclosed |
| CN-105263932-B | Heterocyclic compound | 武田药品工业株式会社 | 2018-01-09 | — | — | CN | disclosed |
| EP-2743263-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOMEPROMAZINE MALEATE | ZCL CHEMICALS LTD (IN) | 2018-01-03 | — | — | EP | disclosed |
| EP-2743263-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOMEPROMAZINE MALEATE | ZCL CHEMICALS LTD (IN) | 2018-01-03 | — | — | EP | disclosed |
| EP-2980089-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| US-9828357-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-28 | — | — | US | disclosed |
| CN-107406369-A | Relaxant behavior modulators | 以西结·戈兰 | 2017-11-28 | — | — | CN | disclosed |
| EP-3230255-A1 | BINGE BEHAVIOR REGULATORS | Golan, Ezekiel (CA) | 2017-10-18 | — | — | EP | disclosed |
| US-20170258728-A1 | CELLULOSE MICROPOWDER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2017-09-14 | — | — | US | disclosed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-2738170-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-9744134-B2 | Orally disintegrating tablet containing bitterness-masking granules | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2017-08-29 | — | — | US | disclosed |
| EP-2810659-B1 | ORALLY DISINTEGRATING TABLET CONTAINING BITTERNESS-MASKING GRANULES | ASAHI CHEMICAL IND (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-20170216251-A1 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | ETHISMOS RESEARCH, INC. | 2017-08-03 | — | — | US | disclosed |
| EP-2759533-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-02 | — | — | EP | disclosed |
| EP-3192791-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-19 | — | — | EP | disclosed |
| EP-3187497-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-20170174682-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| EP-3181616-A1 | CELLULOSE MICROPOWDER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2017-06-21 | — | — | EP | disclosed |
| CN-106795118-A | Heterocyclic compound to they as related orphan receptor (ROR) the GAMMA T inhibitor of retinoids purposes | 武田药品工业株式会社 | 2017-05-31 | — | — | CN | disclosed |
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takenda Pharmaceutical Company Limited (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9650343-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-16 | — | — | US | disclosed |
| EP-3164388-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-9643967-B2 | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9637483-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | disclosed |
| US-9630924-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20170107240-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170105969-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | TOBIRA THERAPEUTICS, INC. | 2017-04-20 | — | — | US | disclosed |
| US-20170096422-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-06 | — | — | US | disclosed |
| EP-3148538-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | Tobira Therapeutics, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9611244-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20170066737-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| WO-2017038909-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | WO | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170049737-A1 | (2R)-2-PROPYLOCTANOIC ACID FOR FUNCTIONAL BRAIN DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-23 | — | — | US | disclosed |
| CN-106459040-A | Heterocyclic compound | 武田药品工业株式会社 | 2017-02-22 | — | — | CN | disclosed |
| US-9573903-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-3124487-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-01 | — | — | EP | disclosed |
| WO-2017014321-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| US-20170020873-A1 | PHARMACEUTICAL COMPOSITIONS | GM PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| WO-2017014323-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| CN-104507940-B | Heterocyclic compounds | 武田药品工业株式会社 | 2017-01-25 | — | — | CN | disclosed |
| CN-104271574-B | Heterocyclic compounds | 武田药品工业株式会社 | 2017-01-25 | — | — | CN | disclosed |
| US-20170015655-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170008885-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-12 | — | — | US | disclosed |
| US-9533966-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-03 | — | — | US | disclosed |
| WO-2016199943-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-15 | — | — | WO | disclosed |
| US-20160361356-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2016-12-15 | — | — | US | disclosed |
| US-9517221-B2 | (2R)-2-propyloctanoic acid for functional brain disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-12-13 | — | — | US | disclosed |
| WO-2016182036-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-17 | — | — | WO | disclosed |
| US-20160326133-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20160326102-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-2050438-B1 | SPHERICAL CRUDE GRANULE AND METHOD FOR PRODUCTION THEREOF | ASAHI CHEMICAL IND (JP) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080124-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-9463191-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| EP-3066094-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-9439865-B2 | Coating film, and granules and tablets each utilizing same | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20160250238-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3052105-A1 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND/OR LUPUS NEPHRITIS | Millennium Pharmaceuticals, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2016123541-A2 | CENICRIVIROC FOR THE TREATMENT OF ENCEPHALITIS INFECTION | TOBIRA THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160176822-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176873-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176872-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| WO-2016092546-A1 | BINGE BEHAVIOR REGULATORS | GOLAN EZEKIEL (IL) | 2016-06-16 | — | — | WO | disclosed |
| US-9365520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| WO-2016088903-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | WO | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| EP-3018123-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-3018126-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-9326974-B2 | Methods and related compositions for the treatment of cancer | STC.UNM (US) | 2016-05-03 | — | — | US | disclosed |
| US-9321757-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-26 | — | — | US | disclosed |
| EP-2994129-A1 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | Euthymic Bioscience, Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20160039811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| WO-2016021742-A1 | HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | WO | disclosed |
| EP-2980089-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2975031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20160008326-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-14 | — | — | US | disclosed |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| WO-2016002968-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
| WO-2015187663-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | TOBIRA THERAPEUTICS, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| EP-2949212-A1 | USE OF OXYGEN ANTAGONISTS FOR EX VIVO PRESERVATION OF TISSUES OR ORGANS | Fred Hutchinson Cancer Research Center (US) | 2015-12-02 | — | — | EP | disclosed |
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9156837-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| US-20150265615-A1 | PHARMACEUTICAL COMPOSITIONS | GM PHARMACEUTICALS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9120776-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| US-9085578-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-21 | — | — | US | disclosed |
| WO-2015088045-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-18 | — | — | WO | disclosed |
| US-20150164064-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2015-06-18 | — | — | US | disclosed |
| US-9050289-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150133451-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | US | disclosed |
| WO-2015068856-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | WO | disclosed |
| US-20150104513-A1 | COATING FILM, AND GRANULES AND TABLETS EACH UTILIZING SAME | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| WO-2015051067-A1 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND/OR LUPUS NEPHRITIS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
| CN-104507940-A | Heterocyclic compounds | TAKEDA PHARMACEUTICAL | 2015-04-08 | — | — | CN | disclosed |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
| US-8992988-B2 | Coating film, and granules and tablets each utilizing same | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-03-31 | — | — | US | disclosed |
| US-20150044286-A1 | ORALLY DISINTEGRATING TABLET CONTAINING BITTERNESS-MASKING GRANULES | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20150045349-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2015-02-12 | — | — | US | disclosed |
| EP-2832734-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
| EP-2298352-B1 | PERCUTANEOUS ABSORPTION ENHANCER AND TRANSDERMAL PREPARATION USING THE SAME | TOA EIYO LTD (JP) | 2015-01-14 | — | — | EP | disclosed |
| EP-2818473-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2161036-B1 | CELLULOSE FINE CORE PARTICLE, AND METHOD FOR PRODUCTION THEREOF | ASAHI KASEI CHEMICALS CORP (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2810659-A1 | ORALLY DISINTEGRATING TABLET CONTAINING BITTERNESS-MASKING GRANULES | Asahi Kasei Chemicals Corporation (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-20140343347-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2014-11-20 | — | — | US | disclosed |
| US-20140315892-A1 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | ETHISMOS RESEARCH, INC. | 2014-10-23 | — | — | US | disclosed |
| US-8835506-B2 | Methods and related compositions for the treatment of cancer | STC.UNM (US) | 2014-09-16 | — | — | US | disclosed |
| US-8822535-B2 | Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140228409-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| EP-2759533-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-07-30 | — | — | EP | disclosed |
| US-8771724-B2 | Percutaneous absorption enhancer and transdermal preparation using the same | TOA EIYO LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-8765187-B2 | Aqueous composition | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-1981487-B1 | LATEX OR PSEUDOLATEX COMPOSITIONS COATINGS AND COATING PROCESSES | FMC CORP (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2743263-A1 | An improved process for the preparation of levomepromazine maleate | ZCL Chemicals Ltd. (IN) | 2014-06-18 | — | — | EP | disclosed |
| EP-2743263-A1 | An improved process for the preparation of levomepromazine maleate | ZCL Chemicals Ltd. (IN) | 2014-06-18 | — | — | EP | disclosed |
| EP-2743263-A1 | An improved process for the preparation of levomepromazine maleate | ZCL Chemicals Ltd. (IN) | 2014-06-18 | — | — | EP | disclosed |
| US-20140163001-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-12 | — | — | US | disclosed |
| EP-2738170-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8741943-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8734830-B2 | Manufacturing method and apparatus of ultrafine particles having uniform particle size distribution | KOREA UNITED PHARM. INC. (KR) | 2014-05-27 | — | — | US | disclosed |
| CN-1901795-B | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HUTCHINSON FRED CANCER RES | 2014-03-26 | — | — | CN | disclosed |
| EP-2700401-A1 | METHOD FOR PRODUCING ADHESIVE PATCH, AND ADHESIVE PATCH | Hisamitsu Pharmaceutical Co., Inc. (JP) | 2014-02-26 | — | — | EP | disclosed |
| US-20140037710-A1 | METHOD FOR PRODUCING PATCH, AND PATCH | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2014-02-06 | — | — | US | disclosed |
| EP-1889839-B1 | Bicyclic compound, production and use as HIV inhibitors | TOBIRA THERAPEUTICS INC (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-1879599-B1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | HUTCHINSON FRED CANCER RES (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-1997902-B1 | SCREENING METHOD | UNIV HIROSHIMA (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-20130210835-A1 | PHARMACEUTICAL COMPOSITIONS | GM PHARMACEUTICAL, INC (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123238-A1 | Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders | ETHISMOS RESEARCH, INC. | 2013-05-16 | — | — | US | disclosed |
| EP-2556830-A1 | Combined effects of topiramate, ondansetron and naltrexone on alcohol consumption | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8367115-B2 | Process for production of crystalline cellulose and tablets containing granules | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8362058-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8329420-B2 | Screening method for a substance that binds to an intracellular region of TLR4 | HIROSHIMA UNIVERSITY (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120302592-A1 | TOPIRAMATE PLUS NALTREXONE FOR THE TREATMENT OF ADDICTIVE DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-8309222-B2 | Coated filaments | COVIDIEN LP (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120282255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE | SUMMIT BIOSCIENCES, INC. | 2012-11-08 | — | — | US | disclosed |
| US-8298585-B2 | Cellulose-based fine core particle and process for producing the same | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120232028-A1 | Bicyclic Compound, Production and Use Thereof | TOBIRA THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2486917-A1 | COATING FILM, AND GRANULES AND TABLETS EACH UTILIZING SAME | Asahi Kasei Chemicals Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120189696-A1 | COATING FILM, AND GRANULES AND TABLETS EACH UTILIZING SAME | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2012-07-26 | — | — | US | disclosed |
| US-8183273-B2 | 8-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide; HIV infectious diseases, chronic rheumatoid arthritis, autoimmune disease, allergic diseases, ischemic brain cell disease | TOBIRA THERAPEUTICS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-1997486-B1 | THERAPEUTIC AGENT FOR FUNCTIONAL BRAIN DISEASE | ONO PHARMACEUTICAL CO (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | disclosed |
| US-20120052479-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | ROTH MARK B (US) | 2012-03-01 | — | — | US | disclosed |
| US-8088414-B2 | Latex or pseudolatex compositions, coatings and coating processes | FMC CORPORATION (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2206702-B1 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS INC (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2366389-A1 | Severe sepsis preventive therapeutic agent | Takeda Pharmaceutical Company Limited (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2363022-A2 | Use of oxygen antagonists for the therapeutic treatment of mammals | Fred Hutchinson Cancer Research Center (US) | 2011-09-07 | — | — | EP | disclosed |
| US-20110200678-A1 | MANUFACTURING METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTION | THE INDUSTRY METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTIO (KR) | 2011-08-18 | — | — | US | disclosed |
| US-7993681-B2 | Exposing isolated tissue to an oxygen antagonist, e.g., a chalcogenide reducing agent, hydrogen sulfide; controlling cellular metabolism by binding to cytochrome oxidase and inhibiting or reducing oxidative phosphorylation activity; nontoxic; preservation; tranplantations; transfusions; transportation | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-28 | — | — | US | disclosed |
| US-7960416-B2 | Oil-in-water emulsion of a 1-carboxylate-6-arylsulfamoyl cyclohexene and synthetic and naturally occurring phospholipids; nitric oxide or cytokine prodution inhibitors; cardiovascular disorders, autoimmune dieseases, septic shock; improved stability during autoclave sterilization | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20110104241-A1 | PERCUTANEOUS ABSORPTION ENHANCER AND TRANSDERMAL PREPARATION USING THE SAME | TOA EIYO LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2298352-A1 | PERCUTANEOUS ABSORPTION ENHANCER AND TRANSDERMAL PREPARATION USING THE SAME | TOA Eiyo Ltd. (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20110065628-A1 | Medication Combinations for the Treatment of Alcoholism and Drug Addiction | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| EP-2260869-A2 | Pharmaceutical product | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2255785-A2 | Stable emulsion composition | Takeda Pharmaceutical Company Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | disclosed |
| US-20100209504-A1 | PROCESS FOR PRODUCTION OF CRYSTALLINE CELLULOSE AND TABLETS CONTAINING GRANULES | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100178332-A1 | CELLULOSE-BASED FINE CORE PARTICLE AND PROCESS FOR PRODUCING THE SAME | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2206702-A1 | Bicyclic compound, production and use thereof | Tobira Therapeutics, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20100172978-A1 | AQUEOUS COMPOSITION | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2010-07-08 | — | — | US | disclosed |
| EP-2184056-A1 | PROCESS FOR PRODUCTION OF TABLETS CONTAINING BOTH CRYSTALLINE CELLULOSE AND GRANULES | Asahi Kasei Chemicals Corporation (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-20100076006-A1 | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2161036-A1 | CELLULOSE FINE CORE PARTICLE, AND METHOD FOR PRODUCTION THEREOF | Asahi Kasei Chemicals Corporation (JP) | 2010-03-10 | — | — | EP | disclosed |
| EP-1423376-B1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS INC (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20100041689-A1 | Combined Effects of Topiramate and Ondansetron on Alcohol Consumption | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100016381-A1 | STABLE EMULSION COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090325999-A1 | PERSONALIZED PHARMACEUTICAL KITS, PACKAGING AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC CONDITIONS | JDP THERAPEUTICS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090317833-A1 | Screening Method | HIROSHIMA UNIVERSITY (JP) | 2009-12-24 | — | — | US | disclosed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-2124909-A2 | COMBINED EFFECTS OF TOPIRAMATE AND ONDANSETRON ON ALCOHOL CONSUMPTION | University Of Virginia Patent Foundation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090209585-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | disclosed |
| US-20090196934-A1 | SPHERICAL ELEMENTARY GRANULE AND METHOD FOR PRODUCTION THEREOF | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2085077-A1 | Coating compositions for controlled relaease formulations | SÜDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHSENFURT (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-07-16 | — | — | US | disclosed |
| US-7541478-B2 | Coumarin derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20090105314-A1 | Pharmaceutical Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-04-23 | — | — | US | disclosed |
| EP-2050438-A1 | SPHERICAL CRUDE GRANULE AND METHOD FOR PRODUCTION THEREOF | Asahi Kasei Chemicals Corporation (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008040002-A9 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | HUTCHINSON FRED CANCER RES (US) | 2009-04-16 | — | — | WO | disclosed |
| EP-2039681-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCTION OF THE DERIVATIVES, AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20090062355-A1 | Pharmaceutical Product | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-03-05 | — | — | US | disclosed |
| WO-2009029308-A1 | MEDICATION COMBINATIONS FOR THE TREATMENT OF ALCOHOLISM AND DRUG ADDICTION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-03-05 | — | — | WO | disclosed |
| US-7495018-B2 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20090036529-A1 | THERAPEUTIC AGENT FOR FUNCTIONAL BRAIN DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090030032-A1 | Bicyclic Compound, Production and Use Thereof | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-2018855-A1 | PHARMACEUTICAL AGENT | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-2018872-A1 | PHARMACEUTICAL PRODUCT | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| US-20090011051-A1 | Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds | FRED HUTCHINSON CANCER RESEARCH CENTER | 2009-01-08 | — | — | US | disclosed |
| EP-2008672-A1 | Coated filaments | Tyco Healthcare Group, LP (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1997486-A1 | THERAPEUTIC AGENT FOR FUNCTIONAL BRAIN DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997902-A1 | SCREENING METHOD | Hiroshima University (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20080268243-A1 | Coated filaments | COVIDIEN LP | 2008-10-30 | — | — | US | disclosed |
| EP-1981487-A1 | LATEX OR PSEUDOLATEX COMPOSITIONS COATINGS AND COATING PROCESSES | FMC CORPORATION (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080226750-A1 | Methods, Compositions and Articles of Manufacture for Treating Shock and Other Adverse Conditions | FRED HUTCHINSON CANCER RESEARCH CENTER | 2008-09-18 | — | — | US | disclosed |
| WO-2008095086-A2 | TOPIRAMATE PLUS NALTREXONE FOR THE TREATMENT OF ADDICTIVE DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080171726-A1 | oxygen antagonists; reducing agent, preservatives; enhancing survivability and achieving stasis or pre-stasis in biological materials (cells, tissues); organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer | ROTH MARK B | 2008-07-17 | — | — | US | disclosed |
| US-20080171725-A1 | Oxygen antagonists; reducing agent, preservatives; enhancing survivability and achieving stasis or pre-stasis in cells or tissues; organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer | ROTH MARK B | 2008-07-17 | — | — | US | disclosed |
| US-20080171093-A1 | Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms | FRED HUTCHINSON CANCER RESEARCH CENTER, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080161287-A1 | Bicyclic compound, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2008-07-03 | — | — | US | disclosed |
| WO-2008077092-A2 | COMBINED EFFECTS OF TOPIRAMATE AND ONDANSETRON ON ALCOHOL CONSUMPTION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008070741-A1 | COMPOSITIONS AND METHODS FOR ENHANCING SURVIVAL AND REDUCING INJURY UNDER ISCHEMIC OR HYPOXIC CONDITIONS | IKARIA, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-7371772-B2 | Bicyclic compound, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20080096924-A1 | Amorphous Composition | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080085329-A1 | Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms | FRED HUTCHINSON CANCER RESEARCH CENTER, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2008040002-A2 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1889839-A1 | Bicyclic compound, production and use as HIV inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
| EP-1879599-A2 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | Fred Hutchinson Cancer Research Center (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1875926-A1 | STABLE EMULSION COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | IKARIA, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| WO-2007124447-A2 | USE OF CHALCOGENIDES FOR TREATING SHOCK AND OTHER ADVERSE CONDITIONS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2007-11-01 | — | — | WO | disclosed |
| US-7288654-B2 | Fused-ring pyridine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LTD (JP) | 2007-10-30 | — | — | US | disclosed |
| EP-1832588-A1 | CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-09-12 | — | — | EP | disclosed |
| EP-1829549-A1 | AMORPHOUS COMPOSITION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070197636-A1 | Coumarin Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| WO-2007092717-A1 | LATEX OR PSEUDOLATEX COMPOSITIONS COATINGS AND COATING PROCESSES | FMC CORPORATION (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070184102-A1 | LATEX OR PSEUDOLATEX COMPOSITIONS, COATINGS AND COATING PROCESSES | FMC CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070179154-A1 | Coumarin derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070166364-A1 | Transdermal Therapeutic System | BEIER CORNELIA | 2007-07-19 | — | — | US | disclosed |
| US-20070166362-A1 | Transdermal and transmucosal preparations | KABUSHIKI KAISHA SANGI (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1797900-A1 | PREPARATION FOR PERCUTANEOUS/PERMUCOSAL ABSORPTION | KABUSHIKI KAISHA SANGI (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | disclosed |
| US-7220473-B2 | Storage stability | HEXAL AG (DE) | 2007-05-22 | — | — | US | disclosed |
| WO-2007047837-A2 | (-)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE, COMPOSITIONS THEREOF, AND USES FOR TREATING ALCOHOL-RELATED DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078113-A1 | Oxygen antagonists; reducing agent, preservatives; enhancing survivability and achieving stasis or pre-stasis in cells or tissues; organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer | FRED HUTCHINSON CANCER RESEARCH CENTER | 2007-04-05 | — | — | US | disclosed |
| US-7199124-B2 | JNK inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| CN-1901795-A | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HUTCHINSON FRED CANCER RES (US) | 2007-01-24 | — | — | CN | disclosed |
| EP-1254659-B1 | STABLE EMULSION COMPOSITIONS | TAKEDA PHARMACEUTICAL (JP) | 2006-11-15 | — | — | EP | disclosed |
| EP-1720850-A1 | COUMARIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006113914-A2 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2006-10-26 | — | — | WO | disclosed |
| CN-1838969-A | Preparation for percutaneous/permucosal absorption | SANGI KK (JP) | 2006-09-27 | — | — | CN | disclosed |
| US-7105572-B2 | Stable emulsion compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-12 | — | — | US | disclosed |
| EP-1689228-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | Fred Hutchinson Cancer Research Center (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060178359-A1 | Tricyclic compound, process for producing the same, and use | SYNGENTA CROP PROTECTION AG (CH) | 2006-08-10 | — | — | US | disclosed |
| US-20060173064-A1 | (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders | LIPPA ARNOLD S | 2006-08-03 | — | — | US | disclosed |
| EP-1684580-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684579-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1338288-B1 | CELLULOSIC PARTICLES FOR PHARMACEUTICAL PREPARATIONS | ASAHI CHEMICAL IND (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060100197-A1 | Fused-ring pyridine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-11 | — | — | US | disclosed |
| CN-1255194-C | Pharmaceutical administration form | MUELLER D (DE) | 2006-05-10 | — | — | CN | disclosed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20060058288-A1 | Severe sepsis preventive therapeutic agent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| US-20060035865-A1 | Lipid-rich plaque regressing agents | TERASHITA ZEN-ICHI | 2006-02-16 | — | — | US | disclosed |
| US-6974806-B2 | Lipid-rich plaque inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-13 | — | — | US | disclosed |
| EP-1593680-A1 | FUSED-RING PYRIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-1593673-A1 | ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-1593681-A1 | TRICYCLIC COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| CN-1222318-C | Cellulosic particle for pharmaceutical preparation | ASAHI CHEMICAL IND (JP) | 2005-10-12 | — | — | CN | disclosed |
| WO-2005082879-A1 | COUMARIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-09 | — | — | WO | disclosed |
| EP-1154776-B1 | PHARMACEUTICAL COMPOSITION CONTAINING DESOXYPEGANINE FOR THE TREATMENT OF ALCOHOLISM | HF ARZNEIMITTELFORSCH GMBH (DE) | 2005-08-17 | — | — | EP | disclosed |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-08-04 | — | — | US | disclosed |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-07-07 | — | — | US | disclosed |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005041655-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041656-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039291-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20050020634-A1 | Coumarin derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1498125-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1495756-A1 | SEVERE SEPSIS PREVENTIVE THERAPEUTIC AGENT | Takeda Chemical Industries, Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040259876-A1 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040253276-A1 | Stable emulsion composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-16 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1471064-A1 | COUMARIN DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| EP-1423376-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1420783-A1 | STABLE EMULSION COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040063946-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040047901-A1 | Storage stability | HEXAL AG (DE) | 2004-03-11 | — | — | US | disclosed |
| US-20040043964-A1 | Cellulosic particle for pharmaceuticals preparation | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2004-03-04 | — | — | US | disclosed |
| CN-1473054-A | Cellulose particles for pharmaceutical preparations | ������������ʽ���� | 2004-02-04 | — | — | CN | disclosed |
| US-20030232809-A1 | Lipid-rich plaque inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1364949-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003014105-A9 | BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-11-20 | — | — | WO | disclosed |
| US-20030212114-A1 | Stable emulsion compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1348443-A1 | COMBINATION DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-6627631-B1 | Desoxypeganine and its pharmaceutically acceptable acid addition salts can be used in the treatment of alcoholism. Said substances are administered preferably in a continuous and controlled manner. The pharmaceutical administration form | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2003-09-30 | — | — | US | disclosed |
| EP-1338288-A1 | CELLULOSIC PARTICLE FOR PHARMACEUTICAL PREPARATION | Asahi Kasei Kabushiki Kaisha (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-1302470-A1 | LIPID-RICH PLAQUE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
| WO-2003013513-A1 | STABLE EMULSION COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003014105-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | disclosed |
| EP-1268474-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1254659-A1 | STABLE EMULSION COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-6413463-B1 | GELATION OF WATER-SOLUBLE CELLULOSE DERIVATIVE IN TEMPERATURE REGION WHERE THE JELLY SHOWS LITTLE CHANGE IN VISCOSITY; UNIFORM; RECYCLING MATERIALS; DRUGS, FOODS, FERTILIZERS | SHIONOGI QUALICAPS CO., LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| EP-1154776-A1 | PHARMACEUTICAL COMPOSITION CONTAINING DESOXYPEGANINE FOR THE TREATMENT OF ALCOHOLISM | LTS Lohmann Therapie-Systeme AG (DE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001074811-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
| EP-1044682-A1 | PROCESS FOR PRODUCING HARD CAPSULE | Shionogi Qualicaps Co., Ltd. (JP) | 2000-10-18 | — | — | EP | disclosed |
| WO-2000048600-A1 | PHARMACEUTICAL COMPOSITION CONTAINING DESOXYPEGANINE FOR THE TREATMENT OF ALCOHOLISM | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2000-08-24 | — | — | WO | disclosed |
| US-5932238-A | Galanthamine containing transdermal applicator for the treatment of alcoholism | LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. (DE) | 1999-08-03 | — | — | US | disclosed |
| CN-1224366-A | Pharmaceutical administration form | MUELLER D (DE) | 1999-07-28 | — | — | CN | disclosed |
| EP-0907388-A1 | PHARMACEUTICAL ADMINISTRATION FORM | Müller, Dieter (DE) | 1999-04-14 | — | — | EP | disclosed |
| US-5830497-A | Medicated plaster containing basic physiologically active agents and/or salts thereof | NITTO DENKO CORPORATION (JP) | 1998-11-03 | — | — | US | disclosed |
| WO-1998000198-A1 | PHARMACEUTICAL ADMINISTRATION FORM | MUELLER DIETER (DE) | 1998-01-08 | — | — | WO | disclosed |
| US-5519017-A | REDUCTION OF DESIRE FOR ALCOHOL BY ADMINISTERING GALANTHAMINE | LTS LOHMANN THERAPIE-SYSTEME GMBH + CO. KG (DE) | 1996-05-21 | — | — | US | disclosed |
| EP-0452837-B1 | Adhesive device for transdermal administration of an active agent | NITTO DENKO CORP (JP) | 1995-08-16 | — | — | EP | disclosed |
| EP-0449247-B1 | Pharmaceutical composition containing Galanthamine for treating alcoholism | LOHMANN THERAPIE SYST LTS (DE) | 1994-07-20 | — | — | EP | disclosed |
| EP-0387751-B1 | Medicated plasters | NITTO DENKO CORP (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5192552-A | Capsules coated with ethyl cellulose and sulfosuccinate in cyclohexane | EGIS GYOGYSZERGYAR (HU) | 1993-03-09 | — | — | US | disclosed |
| US-5176916-A | Plaster layer containing a medicinal ingredient, hydrophobic polymer, absorption promoter, water and a hydrophilic polymer | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| EP-0452837-A2 | Adhesive device for transdermal administration of an active agent | NITTO DENKO CORPORATION (JP) | 1991-10-23 | — | — | EP | disclosed |
| EP-0449247-A2 | Pharmaceutical composition containing Galanthamine for treating alcoholism | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1991-10-02 | — | — | EP | disclosed |
| EP-0143603-B1 | SUGAR-COATED PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1990-10-31 | — | — | EP | disclosed |
| EP-0387751-A2 | Medicated plasters | NITTO DENKO CORPORATION (JP) | 1990-09-19 | — | — | EP | disclosed |
| EP-0251904-B1 | PROCESS FOR THE PREPARATION OF ACIDIC LEVOMEPROMAZINE MALEATE | RHONE-POULENC SANTE (FR) | 1990-01-10 | — | — | EP | disclosed |
| US-4798895-A | Process for preparing levomepromazine hydrogen maleate | RHONE-POULENC SANTE (FR) | 1989-01-17 | — | — | US | disclosed |
| US-4798895-A | Process for preparing levomepromazine hydrogen maleate | RHONE-POULENC SANTE (FR) | 1989-01-17 | — | — | US | disclosed |
| US-4798895-A | Process for preparing levomepromazine hydrogen maleate | RHONE-POULENC SANTE (FR) | 1989-01-17 | — | — | US | disclosed |
| EP-0251904-A1 | Process for the preparation of acidic levomepromazine maleate | RHONE-POULENC SANTE (FR) | 1988-01-07 | — | — | EP | disclosed |
| US-4650666-A | DISCOLORATION INHIBITION | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1987-03-17 | — | — | US | disclosed |
| EP-0143603-A2 | Sugar-coated pharmaceutical composition and method for preparing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1985-06-05 | — | — | EP | disclosed |
| EP-0143603-A2 | Sugar-coated pharmaceutical composition and method for preparing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250238-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | SSB, ME1, SLC16A1 | DRD3 3667/4885DRD2 4292/4885DRD4 4436/4885 |
| US-20250288541-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | DRD3 131/4885DRD2 62/4885DRD4 106/4885 |
| US-20040259876-A1 | Bicyclic compound, production and use thereof | CCR5, CCR1, CCR2 | DRD3 271/4885DRD2 383/4885DRD4 525/4885 |
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | DRD3 3746/4885DRD2 3670/4885DRD4 2044/4885 |
| US-20090030032-A1 | Bicyclic Compound, Production and Use Thereof | CCR5, CCR1, CCR2 | DRD3 434/4885DRD2 467/4885DRD4 561/4885 |
| US-10738004-B2 | Cyclic compound | TLR4, TLR3, TLR1 | DRD3 3986/4885DRD2 3795/4885DRD4 3810/4885 |
| US-10053468-B2 | Heterocyclic compound | RORC, RORB, RORA | DRD3 1553/4885DRD2 2013/4885DRD4 1753/4885 |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | DRD3 1553/4885DRD2 2013/4885DRD4 1753/4885 |
| US-20180085326-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | DRD3 131/4885DRD2 62/4885DRD4 106/4885 |
| US-20210046044-A1 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | ADH1C, ADH1A, ADH5 | DRD3 9/4885DRD2 5/4885DRD4 12/4885 |
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | PTGER4, PTGER1, PTGER3 | DRD3 657/4885DRD2 496/4885DRD4 395/4885 |
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | DRD3 4061/4885DRD2 4349/4885DRD4 3786/4885 |
| US-20140163001-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | DRD3 831/4885DRD2 942/4885DRD4 1347/4885 |
| US-20050020634-A1 | Coumarin derivatives, process for their production and use thereof | CBR1, ACAT2, CBR3 | DRD3 4551/4885DRD2 4802/4885DRD4 4689/4885 |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | DRD3 657/4885DRD2 496/4885DRD4 395/4885 |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | RORC, RORB, RORA | DRD3 2011/4885DRD2 2984/4885DRD4 2899/4885 |
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | DRD3 4571/4885DRD2 4765/4885DRD4 4793/4885 |
| US-20160361356-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | BCL2, BAX, HSF1 | DRD3 4558/4885DRD2 3981/4885DRD4 4676/4885 |
| US-20170174682-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | DRD3 4044/4885DRD2 4343/4885DRD4 4786/4885 |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | DRD3 4255/4885DRD2 4477/4885DRD4 4802/4885 |
| US-20180099000-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | SSB, ME1, SLC16A1 | DRD3 3767/4885DRD2 4364/4885DRD4 4484/4885 |
| US-20060035865-A1 | Lipid-rich plaque regressing agents | NR1H2, NR1H3, LDLR | DRD3 1873/4885DRD2 2544/4885DRD4 2656/4885 |
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | ELANE, MMP8, SERPINC1 | DRD3 2310/4885DRD2 3102/4885DRD4 3688/4885 |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | DRD3 2798/4885DRD2 3116/4885DRD4 4213/4885 |
| US-20080171725-A1 | Oxygen antagonists; reducing agent, preservatives; enhancing survivability and achieving stasis or pre-stasis in cells or tissues; organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer | HSF1, BCL2, HSP90AB1 | DRD3 3521/4885DRD2 1650/4885DRD4 3273/4885 |
| US-20030212114-A1 | Stable emulsion compositions | AHR, NR1H2, NR1H3 | DRD3 477/4885DRD2 283/4885DRD4 1115/4885 |
| US-12084436-B2 | Heterocyclic compound | HDAC1, HDAC5, HDAC6 | DRD3 3266/4885DRD2 3691/4885DRD4 3354/4885 |
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | RORC, RORB, RORA | DRD3 2011/4885DRD2 2984/4885DRD4 2899/4885 |
| US-20170216251-A1 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | ADH1C, ADH1A, ADH5 | DRD3 9/4885DRD2 5/4885DRD4 12/4885 |
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | MAPK13, MMP13, MAPK3 | DRD3 2807/4885DRD2 4157/4885DRD4 3236/4885 |
| US-20120232028-A1 | Bicyclic Compound, Production and Use Thereof | CCR5, CCR1, CCR2 | DRD3 434/4885DRD2 467/4885DRD4 561/4885 |
| US-20090105314-A1 | Pharmaceutical Agent | TLR1, TLR6, TPMT | DRD3 4544/4885DRD2 4399/4885DRD4 4668/4885 |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | HIF1A, HIF1AN, PYGL | DRD3 3743/4885DRD2 2994/4885DRD4 4495/4885 |
| US-20220033371-A1 | DP ANTAGONIST | OPRL1, CNR1, NPSR1 | DRD3 216/4885DRD2 116/4885DRD4 393/4885 |
| US-20110065628-A1 | Medication Combinations for the Treatment of Alcoholism and Drug Addiction | SLC6A3, SLC6A4, ADH5 | DRD3 17/4885DRD2 11/4885DRD4 15/4885 |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | MAPK1, MAP4K2, MAPK4 | DRD3 3757/4885DRD2 4252/4885DRD4 3903/4885 |
| US-20090011051-A1 | Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds | HIF1A, HIF1AN, EGLN3 | DRD3 4871/4885DRD2 4867/4885DRD4 4869/4885 |
| US-11453661-B2 | Heterocyclic compound | HDAC6, HDAC1, HDAC5 | DRD3 3221/4885DRD2 3705/4885DRD4 3630/4885 |
| US-20170105969-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | CCR5, CCR2, CCR1 | DRD3 2506/4885DRD2 2674/4885DRD4 3667/4885 |
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | HDAC6, HDAC1, HDAC5 | DRD3 3361/4885DRD2 3864/4885DRD4 3746/4885 |
| US-20170107240-A1 | AMIDE COMPOUND | RORB, RORC, RORA | DRD3 2546/4885DRD2 2678/4885DRD4 2750/4885 |
| US-20070078113-A1 | Oxygen antagonists; reducing agent, preservatives; enhancing survivability and achieving stasis or pre-stasis in cells or tissues; organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer | HSF1, BCL2, HSP90AB1 | DRD3 3521/4885DRD2 1650/4885DRD4 3273/4885 |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | DRD3 1553/4885DRD2 2013/4885DRD4 1753/4885 |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | RORB, RORC, RORA | DRD3 1532/4885DRD2 1522/4885DRD4 1806/4885 |
| US-20080171726-A1 | oxygen antagonists; reducing agent, preservatives; enhancing survivability and achieving stasis or pre-stasis in biological materials (cells, tissues); organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer | HSF1, HSP90AB1, HSP90AA1 | DRD3 3950/4885DRD2 2115/4885DRD4 3843/4885 |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HSF1, HSP90AB1, HSP90AA1 | DRD3 4719/4885DRD2 4261/4885DRD4 4850/4885 |
| US-20100041689-A1 | Combined Effects of Topiramate and Ondansetron on Alcohol Consumption | SLC6A3, SLC6A4, HTR5A | DRD3 28/4885DRD2 12/4885DRD4 25/4885 |
| US-12350242-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | DRD3 131/4885DRD2 62/4885DRD4 106/4885 |
| US-20090036529-A1 | THERAPEUTIC AGENT FOR FUNCTIONAL BRAIN DISEASE | PYGB, FABP7, GRIK5 | DRD3 1191/4885DRD2 860/4885DRD4 2075/4885 |
| US-20140037710-A1 | METHOD FOR PRODUCING PATCH, AND PATCH | DSG1, DSP, DSC1 | DRD3 2646/4885DRD2 2839/4885DRD4 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.